Generics - Rest of the World, Oncology


Current filters:

Rest of the WorldOncology

Popular Filters

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal


The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region


Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the…

GenericsGP PharmHikma PharmaceuticalsLicensingLutrateOncologyRest of the World

Back to top